Cargando…

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes

BACKGROUND: Extensive research has increased our understanding of the molecular alterations needed for non-small cell lung cancer (NSCLC) development. Deregulation of a pathway including MYCN, HMGA2 and CDKN2A, with the participation of DICER1, is of importance in several solid tumours, and may also...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eide, Hanne A., Halvorsen, Ann Rita, Bjaanæs, Maria Moksnes, Piri, Hossein, Holm, Ruth, Solberg, Steinar, Jørgensen, Lars, Brustugun, Odd Terje, Kiserud, Cecilie Essholt, Helland, Åslaug
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746877/ https://www.ncbi.nlm.nih.gov/pubmed/26858029 http://dx.doi.org/10.1186/s12885-016-2104-9

Ejemplares similares

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2021)

Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
por: Eide, Hanne Astrid, et al.
Publicado: (2016)

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2014)

Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2015)

Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
por: Nordgård, Oddmund, et al.
Publicado: (2013)

Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
por: Halvorsen, Ann Rita, et al.
Publicado: (2019)

Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
por: Haakensen, Vilde D., et al.
Publicado: (2020)

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
por: Halvorsen, Ann Rita, et al.
Publicado: (2020)

The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
por: Öjlert, Åsa Kristina, et al.
Publicado: (2019)

Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses
por: Turzer, Martin, et al.
Publicado: (2010)

Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people
por: Nilssen, Yngvar, et al.
Publicado: (2023)

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
por: McGowan, Marc, et al.
Publicado: (2017)

Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity
por: Turzer, Martin, et al.
Publicado: (2011)

Osteopontin is a prognostic biomarker in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2013)

A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer
por: Halvorsen, Ann Rita, et al.
Publicado: (2016)

EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma
por: Shao, Borong, et al.
Publicado: (2019)

NUT expression in primary lung tumours
por: Lund-Iversen, Marius, et al.
Publicado: (2015)

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
por: Eide, Hanne A., et al.
Publicado: (2018)

Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
por: Berg, Janna, et al.
Publicado: (2021)

Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease
por: Berg, Janna, et al.
Publicado: (2018)

The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed
por: Frafjord, Astri, et al.
Publicado: (2021)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
por: Joly-Battaglini, Albane, et al.
Publicado: (2016)

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2022)

Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
por: Abravan, Azadeh, et al.
Publicado: (2020)

A NOTCH added to metabolomics
por: Brustugun, Odd Terje
Publicado: (2019)

Real-World Data on EGFR and ALK Testing and TKI Usage in Norway—A Nation-Wide Population Study
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2023)

Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
por: Rud, Ane Kongsgaard, et al.
Publicado: (2012)

Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial
por: Horndalsveen, Henrik, et al.
Publicado: (2022)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
por: Haakensen, Vilde Drageset, et al.
Publicado: (2021)

A Controlled Study of Major Depressive Episodes in Long-Term Childhood, Adolescence, and Young Adult Cancer Survivors (The NOR-CAYACS Study)
por: Dahl, Alv A., et al.
Publicado: (2021)

A study of high neuroticism in long-term survivors of childhood, adolescence, and young adult cancers
por: Dahl, Alv A., et al.
Publicado: (2022)

TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
por: Halvorsen, Ann R., et al.
Publicado: (2016)

Norwegian reference data on the Fatigue Questionnaire and the Patient Health Questionnaire-9 and their interrelationship
por: Dahl, Alv A., et al.
Publicado: (2020)

Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway
por: Børø, Siri, et al.
Publicado: (2022)

Assessment of pulmonary (18)F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib
por: Abravan, Azadeh, et al.
Publicado: (2017)

Immune Cell Composition in Human Non-small Cell Lung Cancer
por: Stankovic, Branislava, et al.
Publicado: (2019)

Stage-specific survival has improved for young breast cancer patients since 2000: but not equally
por: Trewin, Cassia Bree, et al.
Publicado: (2020)

Phase- and gender-specific, lifetime, and future costs of cancer: A retrospective population-based registry study
por: Bugge, Christoffer, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sopm9ka6jfrbsmcgmscpfteij8